Download video

FDA Advancing Generic Drugs 2025: Comparative Physicochemical Characterization of Iron Products

500 views

The FDA Learning Cache

6 months ago

FDA Advancing Generic Drugs 2025: Comparative Physicochemical Characterization of Iron Products

FDA Advancing Generic Drugs 2025: Comparative Physicochemical Characterization of Iron Products

FDA Advancing Generic Drug Development 2025: Metered Dose Inhaler \& Dry Powder Inhaler Update
27:53
FDA Advancing Generic Drug Development 2025: Metered Dose Inhaler \& Dry Powder Inhaler Update
by The FDA Learning Cache
FDA Advancing Generic Drug Development 2025: Recommendations for Topical and Mucosal Products
17:36
FDA Advancing Generic Drug Development 2025: Recommendations for Topical and Mucosal Products
by The FDA Learning Cache
FDA Advancing Generic Drugs 2025: Population Selection and Mitigation Strategies in BE Studies
23:46
FDA Advancing Generic Drugs 2025: Population Selection and Mitigation Strategies in BE Studies
by The FDA Learning Cache
Impurities in Peptide Drug Substance, Dinesh Parmar, TIDES Asia 2025
28:39
Impurities in Peptide Drug Substance, Dinesh Parmar, TIDES Asia 2025
by PolyPeptide Group
Setting Specifications for Pharmaceutical Formulations
12:42
Setting Specifications for Pharmaceutical Formulations
by Pharma Learning In Depth
Understanding the US FDA Drug Approval Process | Step-by-Step Explanation for Pharma Professionals
6:52
Understanding the US FDA Drug Approval Process | Step-by-Step Explanation for Pharma Professionals
by Pharmaguideline
Generic Drugs Forum (GDF) 2025 - Day 2
7:44:43
Generic Drugs Forum (GDF) 2025 - Day 2
by U.S. Food and Drug Administration
GDF2025 – D2S20 – Closing Remarks
5:22
GDF2025 – D2S20 – Closing Remarks
by U.S. Food and Drug Administration
GDF2025-D2S08-Common Clinical Deficiencies in ANDAs Containing Comparative Clinical Endpoint Studies
18:21
GDF2025-D2S08-Common Clinical Deficiencies in ANDAs Containing Comparative Clinical Endpoint Studies
by U.S. Food and Drug Administration
GDF 2024 | D2S07 - Post-approval changes in Complex Generics from Drug Product\/CMC Perspectives
25:04
GDF 2024 | D2S07 - Post-approval changes in Complex Generics from Drug Product\/CMC Perspectives
by U.S. Food and Drug Administration
GDF2025 – D1S05 - Request for Reconsideration_Process Overview and Best Practices for FDA Evaluation
20:06
GDF2025 – D1S05 - Request for Reconsideration_Process Overview and Best Practices for FDA Evaluation
by U.S. Food and Drug Administration
GDF 2024 | D2S03-2 - Comparative Analyses Update
12:19
GDF 2024 | D2S03-2 - Comparative Analyses Update
by U.S. Food and Drug Administration
GDF2025 – D1S12 - Considerations when Submitting Proposed Excipient Levels in IIG
17:50
GDF2025 – D1S12 - Considerations when Submitting Proposed Excipient Levels in IIG
by U.S. Food and Drug Administration
How does the FDA approve new drugs?
3:17
How does the FDA approve new drugs?
by U.S. Food and Drug Administration